Loading...
Bilateral Trade Intelligence · $521 Total Trade · 2 Foreign Suppliers · 2 Indian Buyers · DGFT Verified · Updated March 2026
India imported $521 worth of pharmaceutical formulations from Ukraine across 8 verified shipments, from 2 foreign suppliers to 2 Indian buyers. The top suppliers are GLADPHARM LTD. ($518) and COREX UKRAINE LLC ($3). The leading products are Fluconazole ($358) and Clotrimazole ($67). Average shipment value: $65.
| # | Formulation | Value | Share |
|---|---|---|---|
| 1 | Fluconazole | $358 | 68.7% |
| 2 | Clotrimazole | $67 | 12.9% |
| 3 | Levofloxacin | $46 | 8.9% |
| 4 | Ofloxacin | $46 | 8.9% |
| 5 | Serum | $3 | 0.6% |
India imports 5+ pharmaceutical formulations from Ukraine with a combined trade value of $521. Key products include Fluconazole ($358), Clotrimazole ($67), Levofloxacin ($46), Ofloxacin ($46), Serum ($3). These are finished dosage forms — tablets, capsules, injectables, and combination drugs — shipped from Indian manufacturing facilities with FDA, WHO-GMP, and EU GMP certifications. Data from 8 verified Indian Customs (DGFT) shipment records.
These are the top pharmaceutical products exported from India to Ukraine, each with a dedicated trade route analysis page. Click any product to see detailed export data including Indian suppliers, Ukraine buyers, regulatory requirements, and logistics for that specific product corridor. Products include — all finished pharmaceutical formulations verified from Indian Customs (DGFT) records.
2 Indian pharmaceutical companies export finished formulations to Ukraine. Leading exporters include Gladpharm Ltd., Corex Ukraine Llc, . The top exporter accounts for 99.4% of total India–Ukraine pharma exports. Source: Indian Customs (DGFT).
Historical evolution, India's market position, and recent developments
The pharmaceutical trade corridor between Ukraine and India has experienced notable developments from 2022 to 2026. In 2022, the total import value was $521 USD, with 8 shipments from 2 Ukrainian suppliers to 2 Indian buyers. The average shipment value stood at $65 USD. The primary products imported were Fluconazole ($358 USD, 68.7%), Clotrimazole ($67 USD, 12.9%), Levofloxacin ($46 USD, 8.9%), Ofloxacin ($46 USD, 8.9%), and Serum ($3 USD, 0.6%). The leading Ukrainian supplier was GLADPHARM LTD., accounting for $518 USD across 5 shipments, while the top Indian buyer was KUSUM HEALTHCARE PRIVATE LIMITED, importing goods worth $518 USD over 5 shipments.
Ukraine's contribution to India's pharmaceutical imports remains modest. In 2024, Ukraine exported pharmaceutical products valued at $114.36 thousand to India, a slight increase from $111.53 thousand in 2022. This indicates a stable but limited role for Ukraine in India's broader pharmaceutical import landscape. The imports predominantly consist of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections, with Fluconazole being the most significant product.
2 companies in Ukraine import pharmaceutical formulations from India. Top buyers include Kusum Healthcare Private Limited, Lambda Therapeutic Research Limited, . The largest buyer accounts for 99.4% of India–Ukraine pharma imports. Source: Indian Customs (DGFT).
Between 2024 and 2026, there have been no significant policy changes by the Central Drugs Standard Control Organisation (CDSCO) specifically affecting pharmaceutical imports from Ukraine. Trade agreements or regulatory harmonization efforts during this period have not notably impacted this bilateral trade corridor. The steady import values suggest a consistent regulatory environment and trade relations between the two nations.
IMPORT_REGULATORY
Registration process, GMP requirements, import documentation
Ukrainian pharmaceutical companies aiming to export to India must navigate the CDSCO registration process. This involves appointing an authorized Indian agent to represent them in India. The registration requires submission of Form 40, along with a Power of Attorney, Site Master File, and a Free Sale Certificate from the country of origin. The process also includes providing details of the manufacturing facility, quality control measures, and product information. The timeline for registration can vary, but it typically ranges from several months to over a year, depending on the completeness of the application and the efficiency of the review process.
India mandates that foreign manufacturing sites adhere to Good Manufacturing Practice (GMP) standards as outlined by the World Health Organization (WHO). Ukrainian manufacturers must obtain WHO-GMP certification to demonstrate compliance. The CDSCO conducts inspections to verify adherence to these standards. Manufacturers are required to submit a Site Master File detailing their facilities, equipment, and quality control processes. This documentation is crucial for the approval of their products for import into India.
To import pharmaceutical products into India, Ukrainian companies must provide several key documents:
IMPORT_TRENDS
Dominant categories, emerging opportunities, and demand drivers
The majority of India's pharmaceutical imports from Ukraine are finished formulations, particularly in the antifungal and antibacterial categories. Fluconazole, an antifungal agent, constitutes the largest share of imports, followed by Clotrimazole, Levofloxacin, and Ofloxacin, which are used to treat various bacterial infections. This trend indicates a demand for specific therapeutic agents not extensively produced domestically.
India imports specialized pharmaceutical products from Ukraine, such as Fluconazole and Clotrimazole, which are essential for treating specific infections. These products are not widely manufactured within India, highlighting the role of Ukrainian suppliers in fulfilling niche market needs. The importation of these specialized drugs underscores the importance of international collaboration in addressing India's diverse healthcare requirements.
The demand for Ukrainian pharmaceutical products in India is driven by several factors:
IMPORT_POLICY
Tariff structure, trade agreements, IP and patent landscape
India's import tariff structure for pharmaceutical formulations includes:
These duties and taxes are subject to periodic revisions and should be verified with the latest government notifications.
As of March 2026, there are no specific Free Trade Agreements (FTAs) between India and Ukraine that offer preferential duty rates for pharmaceutical imports. Both countries are members of the World Trade Organization (WTO), which provides a framework for trade relations, but does not include specific provisions for pharmaceutical products between them.
India's patent regime, particularly Section 3(d) of the Indian Patents Act, aims to prevent evergreening of patents and ensures that only genuine innovations receive patent protection. This can impact the importation of certain pharmaceutical products. The National Pharmaceutical Pricing Authority (NPPA) regulates the prices of essential drugs, including imported ones, to make them affordable for the Indian population. Imported drugs may be subject to price controls, which can influence their market dynamics.
IMPORT_LOGISTICS
Shipping routes, port infrastructure, cold chain compliance
Pharmaceutical shipments from Ukraine to India typically utilize sea routes, with major ports such as Odessa in Ukraine and Mumbai or Chennai in India serving as key transit points. The transit time for sea freight is approximately 30 to 40 days, depending on the specific ports and shipping conditions. Air freight is also an option, offering faster delivery times of 7 to 10 days, but at a higher cost. The reliability of these routes is generally high, though subject to geopolitical and logistical factors.
In Ukraine, the Port of Odessa is a primary export hub for pharmaceutical products, equipped with facilities to handle bulk and containerized shipments. In India, ports such as Mumbai and Chennai are well-equipped to handle pharmaceutical imports, with dedicated terminals for medical goods, ensuring compliance with health and safety standards.
Upon arrival at Indian ports, pharmaceutical imports undergo customs clearance, which includes verification of documentation, inspection of goods, and payment of applicable duties and taxes. The CDSCO conducts quality checks to ensure compliance with Indian standards. Cold chain management is critical for temperature-sensitive products; importers must ensure that their logistics partners maintain the required temperature ranges throughout transit and storage. Compliance with Good Distribution Practice (GDP) is mandatory to maintain product integrity.
IMPORT_OPPORTUNITY
Market size, healthcare system, growth outlook
Despite being a major pharmaceutical manufacturer, India imports specific drugs from Ukraine due to factors such as patent protection, technology gaps, and the need for high-quality formulations. The domestic production of certain specialized drugs may be limited, leading to reliance on imports to meet healthcare demands.
Ukrainian pharmaceutical companies like GLADPHARM LTD. and COREX UKRAINE LLC supply products to India, primarily through partnerships with Indian buyers such as KUSUM HEALTHCARE PRIVATE LIMITED and LAMBDA THERAPEUTIC RESEARCH LIMITED. These collaborations facilitate market entry and distribution within India, leveraging local expertise and networks.
India's Atmanirbhar Bharat initiative and the Production Linked Incentive (PLI) scheme aim to boost domestic manufacturing capabilities, potentially reducing the need for
India exported pharmaceuticals worth $521 to Ukraine across 8 verified shipments.
1. GLADPHARM LTD. — $518. 2. COREX UKRAINE LLC — $3. Total: 2 suppliers.
1. KUSUM HEALTHCARE PRIVATE LIMITED — $518. 2. LAMBDA THERAPEUTIC RESEARCH LIMITED — $3. 2 buyers total.
1. Fluconazole ($358, 68.7%); 2. Clotrimazole ($67, 12.9%); 3. Levofloxacin ($46, 8.9%); 4. Ofloxacin ($46, 8.9%); 5. Serum ($3, 0.6%)
Export: . Import: .
India's cost-competitive generic drug manufacturing, WHO-GMP certified facilities, and broad product portfolio. This $521 corridor reflects quality compliance and pricing advantages.
WHO-GMP certification, EU GMP approval (for EU markets), product dossier registration (CTD format), and ICH guideline compliance.
$65 per consignment across 8 shipments.
2 Indian companies. Largest: GLADPHARM LTD. with $518.
TransData Nexus covers 2 active exporters with shipment history and trade values at transdatanexus.com.
Access complete shipment records, supplier intelligence, buyer histories, and price analytics for all 8 shipments.
Data sourced from Indian Customs (DGFT) records. Verify regulatory status with the agencies above.
Pharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormareAll trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
2 Exporters
2 buyers tracked
Expert-Reviewed
By pharmaceutical trade specialists